Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo-controlled clinical trial.

King JN, Martin M, Chetboul V, Ferasin L, French AT, Strehlau G, Seewald W, Smith SGW, Swift ST, Roberts SL, Harvey AM, Little CJL, Caney SMA, Simpson KE, Sparkes AH, Mardell EJ, Bomassi E, Muller C, Sauvage JP, Diquélou A, Schneider MA, Brown LJ, Clarke DD, Rousselot JF.

J Vet Intern Med. 2019 Sep 27. doi: 10.1111/jvim.15572. [Epub ahead of print]

2.

ZooArchNet: Connecting zooarchaeological specimens to the biodiversity and archaeology data networks.

LeFebvre MJ, Brenskelle L, Wieczorek J, Kansa SW, Kansa EC, Wallis NJ, King JN, Emery KF, Guralnick R.

PLoS One. 2019 Apr 12;14(4):e0215369. doi: 10.1371/journal.pone.0215369. eCollection 2019.

3.

Probing molecular dynamics with hyperpolarized ultrafast Laplace NMR using a low-field, single-sided magnet.

King JN, Fallorina A, Yu J, Zhang G, Telkki VV, Hilty C, Meldrum T.

Chem Sci. 2018 Jun 28;9(28):6143-6149. doi: 10.1039/c8sc01329b. eCollection 2018 Jul 28.

4.

Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs.

King JN, Christinaz C, Strehlau G, Hornfeld J.

J Vet Pharmacol Ther. 2018 Jun;41(3):485-489. doi: 10.1111/jvp.12475. Epub 2018 Feb 2.

PMID:
29392741
5.

Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.

King JN, Hirakawa A, Sonobe J, Otaki H, Sakakibara N, Seewald W, Forster S.

J Vet Sci. 2018 Jan 31;19(1):117-128. doi: 10.4142/jvs.2018.19.1.117.

6.

Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.

King JN, Font A, Rousselot JF, Ash RA, Bonfanti U, Brovida C, Crowe ID, Lanore D, Pechereau D, Seewald W, Strehlau G.

J Vet Intern Med. 2017 Jul;31(4):1113-1122. doi: 10.1111/jvim.14726. Epub 2017 Jul 1.

7.

Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.

Friton G, Thompson CM, Karadzovska D, King S, King JN.

BMC Vet Res. 2017 Jun 26;13(1):197. doi: 10.1186/s12917-017-1100-x.

8.

Safety of a benazepril and pimobendan combination tablet in adult healthy dogs.

Kuntz EA, Strehlau G, Giraudel JM, King JN.

J Vet Pharmacol Ther. 2018 Feb;41(1):105-116. doi: 10.1111/jvp.12423. Epub 2017 Jun 26.

PMID:
28649790
9.

Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.

Friton G, Thompson C, Karadzovska D, King S, King JN.

J Vet Intern Med. 2017 May;31(3):832-841. doi: 10.1111/jvim.14698.

10.

Evaluation of cardiovascular effects of intravenous robenacoxib in dogs.

Desevaux C, Marotte-Weyn AA, Champeroux P, King JN.

J Vet Pharmacol Ther. 2017 Dec;40(6):e62-e64. doi: 10.1111/jvp.12411. Epub 2017 Apr 29.

PMID:
28457010
11.

Neuropsychiatric Associations With Gender, Illness Duration, Work Disability, and Motor Subtype in a U.S. Functional Neurological Disorders Clinic Population.

Matin N, Young SS, Williams B, LaFrance WC Jr, King JN, Caplan D, Chemali Z, Weilburg JB, Dickerson BC, Perez DL.

J Neuropsychiatry Clin Neurosci. 2017 Fall;29(4):375-382. doi: 10.1176/appi.neuropsych.16110302. Epub 2017 Apr 28.

PMID:
28449634
12.

Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Rossmeisl JH, Hall-Manning K, Robertson JL, King JN, Davalos RV, Debinski W, Elankumaran S.

Onco Targets Ther. 2017 Apr 12;10:2077-2085. doi: 10.2147/OTT.S132964. eCollection 2017.

13.

Preliminary Predictors of Initial Attendance, Symptom Burden, and Motor Subtype in a US Functional Neurological Disorders Clinic Population.

Perez DL, Young SS, King JN, Guarino AJ, Dworetzky BA, Flaherty A, Chemali Z, Caplan D, Dickerson BC.

Cogn Behav Neurol. 2016 Dec;29(4):197-205.

PMID:
27984257
14.

Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats.

Pelligand L, Soubret A, King JN, Elliott J, Mochel JP.

CPT Pharmacometrics Syst Pharmacol. 2016 Nov;5(11):625-635. doi: 10.1002/psp4.12141. Epub 2016 Oct 22.

16.

Evaluation of the dose-response relationship of oral robenacoxib in urate crystal-induced acute stifle synovitis in dogs.

Borer LR, Seewald W, Peel JE, King JN.

J Vet Pharmacol Ther. 2017 Apr;40(2):148-157. doi: 10.1111/jvp.12348. Epub 2016 Aug 5.

PMID:
27493016
17.

Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats.

King JN, Panteri A, Graille M, Seewald W, Friton G, Desevaux C.

BMC Vet Res. 2016 Jun 23;12(1):124. doi: 10.1186/s12917-016-0734-4.

18.

Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs.

Panteri A, Kukk A, Desevaux C, Seewald W, King JN.

J Vet Pharmacol Ther. 2017 Jan;40(1):44-56. doi: 10.1111/jvp.12325. Epub 2016 Jun 15.

PMID:
27302598
19.

Ultrafast Multidimensional Laplace NMR Using a Single-Sided Magnet.

King JN, Lee VJ, Ahola S, Telkki VV, Meldrum T.

Angew Chem Int Ed Engl. 2016 Apr 11;55(16):5040-3. doi: 10.1002/anie.201511859. Epub 2016 Mar 9.

PMID:
26960011
20.

Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.

Pelligand L, Suemanotham N, King JN, Seewald W, Syme H, Smith K, Lees P, Elliott J.

BMC Vet Res. 2015 Dec 3;11:296. doi: 10.1186/s12917-015-0598-z.

21.

Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo-controlled clinical trial.

King JN, King S, Budsberg SC, Lascelles BD, Bienhoff SE, Roycroft LM, Roberts ES.

J Feline Med Surg. 2016 Aug;18(8):632-42. doi: 10.1177/1098612X15590870. Epub 2015 Jun 9.

PMID:
26058587
22.

Robenacoxib versus meloxicam for the control of peri-operative pain and inflammation associated with orthopaedic surgery in cats: a randomised clinical trial.

Speranza C, Schmid V, Giraudel JM, Seewald W, King JN.

BMC Vet Res. 2015 Mar 26;11:79. doi: 10.1186/s12917-015-0391-z.

23.

Efficacy and acceptability of the new oral phosphate binder Lenziaren(®) in healthy cats fed a renal diet.

King JN, Delport PC, Luus HG, Erasmus HL, Barnes PM, Speranza C.

J Vet Pharmacol Ther. 2015 Jun;38(3):278-89. doi: 10.1111/jvp.12173. Epub 2014 Nov 3.

PMID:
25363785
24.

Efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® in healthy cats fed a standard diet.

King JN, Erasmus HL, Delport PC, Bester IC, Seewald W.

BMC Vet Res. 2014 Oct 28;10:258. doi: 10.1186/s12917-014-0258-8.

25.

Characterization of aging and solvent treatments of painted surfaces using single-sided NMR.

Fife GR, Stabik B, Kelley AE, King JN, Blümich B, Hoppenbrouwers R, Meldrum T.

Magn Reson Chem. 2015 Jan;53(1):58-63. doi: 10.1002/mrc.4164. Epub 2014 Oct 21.

PMID:
25332115
26.

Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.

Pelligand L, King JN, Hormazabal V, Toutain PL, Elliott J, Lees P.

J Vet Pharmacol Ther. 2014 Aug;37(4):354-66. doi: 10.1111/jvp.12107. Epub 2014 Mar 15.

PMID:
24628410
27.

The authors respond.

Martel E, Egner B, Brown SA, King JN, Laveissiere A, Champeroux P, Richard S.

J Feline Med Surg. 2013 Dec;15(12):1169-70. No abstract available.

PMID:
24400325
28.

Comparison of high-definition oscillometry -- a non-invasive technology for arterial blood pressure measurement -- with a direct invasive method using radio-telemetry in awake healthy cats.

Martel E, Egner B, Brown SA, King JN, Laveissiere A, Champeroux P, Richard S.

J Feline Med Surg. 2013 Dec;15(12):1104-13. doi: 10.1177/1098612X13495025. Epub 2013 Jun 28.

PMID:
23813147
29.

Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.

Fink M, Letellier I, Peyrou M, Mochel JP, Jung M, King JN, Gruet P, Giraudel JM.

Res Vet Sci. 2013 Oct;95(2):580-7. doi: 10.1016/j.rvsc.2013.04.021. Epub 2013 May 31.

PMID:
23726662
31.

Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.

King JN, Jung M, Maurer MP, Schmid VB, Seewald W, Lees P.

Am J Vet Res. 2013 Mar;74(3):465-72. doi: 10.2460/ajvr.74.3.465.

PMID:
23438125
32.

MRI findings in 232 horses with lameness localized to the metacarpo(tarso)phalangeal region and without a radiographic diagnosis.

King JN, Zubrod CJ, Schneider RK, Sampson SN, Roberts G.

Vet Radiol Ultrasound. 2013 Jan-Feb;54(1):36-47. doi: 10.1111/j.1740-8261.2012.01983.x. Epub 2012 Oct 1.

PMID:
23020207
33.

Self/unplanned extubation: safety, surveillance, and monitoring of the mechanically ventilated patient.

King JN, Elliott VA.

Crit Care Nurs Clin North Am. 2012 Sep;24(3):469-79. doi: 10.1016/j.ccell.2012.06.004. Epub 2012 Jul 11.

PMID:
22920470
34.

Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial.

Edamura K, King JN, Seewald W, Sakakibara N, Okumura M.

J Vet Med Sci. 2012 Sep;74(9):1121-31. Epub 2012 May 17.

36.

Comparison of oral robenacoxib and ketoprofen for the treatment of acute pain and inflammation associated with musculoskeletal disorders in cats: a randomised clinical trial.

Sano T, King JN, Seewald W, Sakakibara N, Okumura M.

Vet J. 2012 Aug;193(2):397-403. doi: 10.1016/j.tvjl.2012.02.008. Epub 2012 Mar 18.

PMID:
22430026
37.

Comparison of injectable robenacoxib versus meloxicam for peri-operative use in cats: results of a randomised clinical trial.

Kamata M, King JN, Seewald W, Sakakibara N, Yamashita K, Nishimura R.

Vet J. 2012 Jul;193(1):114-8. doi: 10.1016/j.tvjl.2011.11.026. Epub 2012 Jan 9.

PMID:
22227226
38.

Evaluation of oral robenacoxib for the treatment of postoperative pain and inflammation in cats: results of a randomized clinical trial.

King S, Roberts ES, Roycroft LM, King JN.

ISRN Vet Sci. 2012 Jul 1;2012:794148. doi: 10.5402/2012/794148. Print 2012.

39.

Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation.

Pelligand L, King JN, Toutain PL, Elliott J, Lees P.

J Vet Pharmacol Ther. 2012 Feb;35(1):19-32. doi: 10.1111/j.1365-2885.2011.01288.x. Epub 2011 Jul 18.

PMID:
21767277
40.

Safety of oral robenacoxib in the cat.

King JN, Hotz R, Reagan EL, Roth DR, Seewald W, Lees P.

J Vet Pharmacol Ther. 2012 Jun;35(3):290-300. doi: 10.1111/j.1365-2885.2011.01320.x. Epub 2011 Jul 8.

PMID:
21736587
41.

Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.

King JN, Arnaud JP, Goldenthal EI, Gruet P, Jung M, Seewald W, Lees P.

J Vet Pharmacol Ther. 2011 Jun;34(3):298-311. doi: 10.1111/j.1365-2885.2010.01209.x.

PMID:
21492194
42.

Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial.

Reymond N, Speranza C, Gruet P, Seewald W, King JN.

J Vet Pharmacol Ther. 2012 Apr;35(2):175-83. doi: 10.1111/j.1365-2885.2011.01297.x. Epub 2011 Apr 12.

PMID:
21480932
43.

Mechanical function, glycolysis, and ultrastructure of perfused working mouse hearts following thoracic aortic constriction.

Dunn ME, Manfredi TG, Cosmas AC, Vetter FJ, King JN, Rodgers RL.

Cardiovasc Pathol. 2011 Nov-Dec;20(6):343-51. doi: 10.1016/j.carpath.2010.12.003. Epub 2011 Feb 4.

PMID:
21296006
44.
45.

Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Silber HE, Burgener C, Letellier IM, Peyrou M, Jung M, King JN, Gruet P, Giraudel JM.

Pharm Res. 2010 Dec;27(12):2633-45. doi: 10.1007/s11095-010-0262-z. Epub 2010 Oct 5.

PMID:
20922466
46.

In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study.

Schmid VB, Seewald W, Lees P, King JN.

J Vet Pharmacol Ther. 2010 Oct;33(5):444-52. doi: 10.1111/j.1365-2885.2010.01166.x.

PMID:
20840388
47.

Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.

Martin MW, Stafford Johnson MJ, Strehlau G, King JN.

J Small Anim Pract. 2010 Aug;51(8):428-36. doi: 10.1111/j.1748-5827.2010.00966.x.

PMID:
20670255
48.

Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats.

Giraudel JM, Gruet P, Alexander DG, Seewald W, King JN.

Am J Vet Res. 2010 Jul;71(7):710-9. doi: 10.2460/ajvr.71.7.710.

PMID:
20594071
49.

Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.

Schmid VB, Spreng DE, Seewald W, Jung M, Lees P, King JN.

J Vet Pharmacol Ther. 2010 Apr;33(2):118-31. doi: 10.1111/j.1365-2885.2009.01117.x.

PMID:
20444036
50.

In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.

King JN, Rudaz C, Borer L, Jung M, Seewald W, Lees P.

Res Vet Sci. 2010 Jun;88(3):497-506. doi: 10.1016/j.rvsc.2009.11.002. Epub 2009 Dec 11.

PMID:
20004922

Supplemental Content

Support Center